Carcinogenesis models for risk assessment. 1997

A Kopp-Schneider
Department of Biostatistics, German Cancer Research Centre, Heidelberg, Germany. kopp@dkfz-heidelberg.de

This article provides an overview of different types of carcinogenesis models and discusses their use for risk assessment. One class of model, the multistage model, is especially suited for risk assessment purposes because it uses biological information about the process of carcinogenesis and the quantities of interest, such as time to tumour and number and size distribution of premalignant tumours, can be derived explicitly, allowing for standard statistical techniques to be used. The mathematical methods necessary for the treatment of multistage models are developed and the application of multistage models in risk assessment is discussed.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009385 Neoplastic Processes The pathological mechanisms and forms taken by tissue during degeneration into a neoplasm and its subsequent activity. Processes, Neoplastic
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D018570 Risk Assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988) Assessment, Risk,Benefit-Risk Assessment,Risk Analysis,Risk-Benefit Assessment,Health Risk Assessment,Risks and Benefits,Analysis, Risk,Assessment, Benefit-Risk,Assessment, Health Risk,Assessment, Risk-Benefit,Benefit Risk Assessment,Benefit-Risk Assessments,Benefits and Risks,Health Risk Assessments,Risk Analyses,Risk Assessment, Health,Risk Assessments,Risk Benefit Assessment,Risk-Benefit Assessments

Related Publications

A Kopp-Schneider
November 1991, Human & experimental toxicology,
A Kopp-Schneider
December 1994, Risk analysis : an official publication of the Society for Risk Analysis,
A Kopp-Schneider
January 1976, Annals of the New York Academy of Sciences,
A Kopp-Schneider
December 1978, Science (New York, N.Y.),
A Kopp-Schneider
December 1978, Science (New York, N.Y.),
A Kopp-Schneider
December 1978, Science (New York, N.Y.),
A Kopp-Schneider
December 1978, Science (New York, N.Y.),
Copied contents to your clipboard!